PARP over-expression was associated with aggressive clinical parameters such as larger tumor size (p = 0.0136), distant metastasis (p = 0.0003), stage IV tumors (p = 0.0006), grade 3 tumors (p < 0.0001) and triple negative breast cancers (p < 0.0001). Here, PARP1 is linked to triple-negative breast carcinoma.